Norepinephrine Kabi (Noradrenaline Tartrate)

Norepinephrine, the active ingredient in Norepinephrine Kabi, is a sympathomimetic presented as a sterile aqueous solution for intravenous use. It acts as a potent vasopressor to increase arterial pressure in patients experiencing hypotension, septic shock, or cardiac arrest, helping to maintain adequate organ perfusion.

GNH USA supplies Norepinephrine Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures timely delivery in compliance with global regulatory standards.

Norepinephrine Kabi is employed as a vasopressor in critical‑care settings to support circulatory function.

- Hypotension: Restores systemic vascular resistance to raise blood pressure in acute low‑pressure states. - Septic shock: Improves mean arterial pressure and organ perfusion when fluid resuscitation is insufficient. - Cardiac arrest: Provides immediate vasoconstriction to augment coronary and cerebral perfusion during resuscitation efforts.

Norepinephrine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Tachycardia: Elevated heart rate due to beta‑1 stimulation. - Headache: Resulting from rapid changes in vascular tone. - Anxiety or restlessness: Central nervous system response to catecholamine surge. - Peripheral ischemia: Reduced blood flow to extremities. - Nausea or vomiting: Gastrointestinal irritation. - Extravasation injury: Local tissue damage if infusion leaks.

Serious or Rare Side Effects: - Myocardial ischemia: Reduced coronary perfusion from excessive vasoconstriction. - Severe hypertension: Overcorrection leading to dangerously high blood pressure. - Cardiac arrhythmias: Potential for life‑threatening rhythm disturbances. - Tissue necrosis at infusion site: Resulting from extravasation. - Pulmonary edema: Fluid accumulation due to increased afterload. - Cardiac arrest: Rare but possible if severe arrhythmia occurs.

When using Norepinephrine Kabi, clinicians should observe several safety measures.

- Monitor blood pressure: Continuous invasive monitoring is recommended to guide titration. - Adjust dose: Titrate to achieve target mean arterial pressure while avoiding excessive hypertension. - Assess cardiac function: Use caution in patients with known myocardial ischemia or severe heart failure. - Avoid extravasation: Prefer central venous access and inspect infusion sites regularly. - Review concomitant drugs: Evaluate other vasoactive agents for additive effects. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Norepinephrine Kabi can interact with several medications, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: May precipitate hypertensive crisis due to synergistic catecholamine effects. - Beta‑blockers: Can blunt the desired increase in cardiac output. - Tricyclic antidepressants: Heighten risk of arrhythmias and hypertension.

Moderate Interactions (Monitor Closely): - ACE inhibitors: May cause additive hypotensive effects when norepinephrine is tapered. - Calcium channel blockers: Can influence vascular tone and modify response to norepinephrine.